Sun Pharma and Bayer announced that they have signed an agreement to market and distribute a second brand of Finerenone in India. Finerenone, a patented medicine is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease associated with type 2 diabetes mellitus, says a company statement.
Under the agreement, Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand, Lyvelsa. Finerenone was first launched by Bayer under the brand name Kerendia in 2022
Shweta Rai, Country Division Head for Bayer’s pharmaceuticals business in South Asia said, “With the introduction of a second brand of Finerenone in India, through our partnership with Sun Pharma, we are advancing Bayer’s commitment of making healthcare accessible to as many patients as possible. India has a high incidence of diabetes and associated renal and cardiac conditions. The true value of innovations like Finerenone can only be fully realized after they reach all deserving patients.”
Kirti Ganorkar, CEO – India Business, Sun Pharma said, “We are happy to collaborate with Bayer to provide patients access to a new treatment which slows down the progression of chronic kidney disease and reduces the risk of kidney failure associated with Type-2 diabetes’’
Under the agreement, Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand, Lyvelsa. Finerenone was first launched by Bayer under the brand name Kerendia in 2022
Shweta Rai, Country Division Head for Bayer’s pharmaceuticals business in South Asia said, “With the introduction of a second brand of Finerenone in India, through our partnership with Sun Pharma, we are advancing Bayer’s commitment of making healthcare accessible to as many patients as possible. India has a high incidence of diabetes and associated renal and cardiac conditions. The true value of innovations like Finerenone can only be fully realized after they reach all deserving patients.”
Kirti Ganorkar, CEO – India Business, Sun Pharma said, “We are happy to collaborate with Bayer to provide patients access to a new treatment which slows down the progression of chronic kidney disease and reduces the risk of kidney failure associated with Type-2 diabetes’’
